Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors (original) (raw)

References

  1. Alexandrov, L.B., Nik-Zainal, S., Wedge, D.C., Campbell, P.J. & Stratton, M.R. Deciphering signatures of mutational processes operative in human cancer. Cell Rep. 3, 246–259 (2013).
    CAS PubMed PubMed Central Google Scholar
  2. Alexandrov, L.B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013).
    CAS PubMed PubMed Central Google Scholar
  3. Roberts, S.A. et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat. Genet. 45, 970–976 (2013).
    CAS PubMed PubMed Central Google Scholar
  4. Burns, M.B. et al. APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 494, 366–370 (2013).
    CAS PubMed PubMed Central Google Scholar
  5. Nik-Zainal, S. et al. Mutational processes molding the genomes of 21 breast cancers. Cell 149, 979–993 (2012).
    CAS PubMed PubMed Central Google Scholar
  6. Saraconi, G., Severi, F., Sala, C., Mattiuz, G. & Conticello, S.G. The RNA editing enzyme APOBEC1 induces somatic mutations and a compatible mutational signature is present in esophageal adenocarcinomas. Genome Biol. 15, 417 (2014).
    PubMed PubMed Central Google Scholar
  7. Swanton, C., McGranahan, N., Starrett, G.J. & Harris, R.S. APOBEC enzymes: mutagenic fuel for cancer evolution and heterogeneity. Cancer Discov. 5, 704–712 (2015).
    CAS PubMed PubMed Central Google Scholar
  8. Chan, K. et al. An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers. Nat. Genet. 47, 1067–1072 (2015).
    CAS PubMed PubMed Central Google Scholar
  9. Burns, M.B., Temiz, N.A. & Harris, R.S. Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat. Genet. 45, 977–983 (2013).
    CAS PubMed PubMed Central Google Scholar
  10. Rothman, N. et al. A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat. Genet. 42, 978–984 (2010).
    CAS PubMed PubMed Central Google Scholar
  11. Matsuda, K. et al. Genome-wide association study identified SNP on 15q24 associated with bladder cancer risk in Japanese population. Hum. Mol. Genet. 24, 1177–1184 (2015).
    CAS PubMed Google Scholar
  12. Kidd, J.M., Newman, T.L., Tuzun, E., Kaul, R. & Eichler, E.E. Population stratification of a common APOBEC gene deletion polymorphism. PLoS Genet. 3, e63 (2007).
    PubMed PubMed Central Google Scholar
  13. Caval, V., Suspène, R., Shapira, M., Vartanian, J.P. & Wain-Hobson, S. A prevalent cancer susceptibility APOBEC3A hybrid allele bearing APOBEC3B, 3′UTR enhances chromosomal DNA damage. Nat. Commun. 5, 5129 (2014).
    CAS PubMed Google Scholar
  14. Qi, G., Xiong, H. & Zhou, C. APOBEC3 deletion polymorphism is associated with epithelial ovarian cancer risk among Chinese women. Tumour Biol. 35, 5723–5726 (2014).
    CAS PubMed Google Scholar
  15. Xuan, D. et al. APOBEC3 deletion polymorphism is associated with breast cancer risk among women of European ancestry. Carcinogenesis 34, 2240–2243 (2013).
    CAS PubMed PubMed Central Google Scholar
  16. Long, J. et al. A common deletion in the APOBEC3 genes and breast cancer risk. J. Natl. Cancer Inst. 105, 573–579 (2013).
    CAS PubMed PubMed Central Google Scholar
  17. Nik-Zainal, S. et al. Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer. Nat. Genet. 46, 487–491 (2014).
    CAS PubMed PubMed Central Google Scholar
  18. Figueroa, J.D. et al. Genome-wide association study identifies multiple loci associated with bladder cancer risk. Hum. Mol. Genet. 23, 1387–1398 (2014).
    CAS PubMed Google Scholar
  19. Michailidou, K. et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat. Genet. 45, 353–361 (2013).
    CAS PubMed PubMed Central Google Scholar
  20. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507, 315–322 (2014).
  21. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490, 61–70 (2012).
  22. Roberts, S.A. & Gordenin, D.A. Hypermutation in human cancer genomes: footprints and mechanisms. Nat. Rev. Cancer 14, 786–800 (2014).
    CAS PubMed PubMed Central Google Scholar
  23. Mifsud, B. et al. Mapping long-range promoter contacts in human cells with high-resolution capture Hi-C. Nat. Genet. 47, 598–606 (2015).
    CAS PubMed Google Scholar
  24. Göhler, S. et al. Impact of functional germline variants and a deletion polymorphism in APOBEC3A and APOBEC3B on breast cancer risk and survival in a Swedish study population. J. Cancer Res. Clin. Oncol. 142, 273–276 (2016).
    PubMed Google Scholar
  25. Refsland, E.W. et al. Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Res. 38, 4274–4284 (2010).
    CAS PubMed PubMed Central Google Scholar
  26. Land, A.M. et al. Endogenous APOBEC3A DNA cytosine deaminase is cytoplasmic and nongenotoxic. J. Biol. Chem. 288, 17253–17260 (2013).
    CAS PubMed PubMed Central Google Scholar
  27. Mussil, B. et al. Human APOBEC3A isoforms translocate to the nucleus and induce DNA double strand breaks leading to cell stress and death. PLoS One 8, e73641 (2013).
    CAS PubMed PubMed Central Google Scholar
  28. Akre, M.K. et al. Mutation processes in 293-based clones overexpressing the DNA cytosine deaminase APOBEC3B. PLoS One 11, e0155391 (2016).
    PubMed PubMed Central Google Scholar
  29. Sheehy, A.M., Gaddis, N.C., Choi, J.D. & Malim, M.H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418, 646–650 (2002).
    CAS PubMed Google Scholar
  30. Bonvin, M. et al. Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication. Hepatology 43, 1364–1374 (2006).
    CAS PubMed Google Scholar
  31. Wang, Z. et al. APOBEC3 deaminases induce hypermutation in human papillomavirus 16 DNA upon β interferon stimulation. J. Virol. 88, 1308–1317 (2014).
    PubMed PubMed Central Google Scholar
  32. Strander, H. & Cantell, K. Production of interferon by human leukocytes in vitro. Ann. Med. Exp. Biol. Fenn. 44, 265–273 (1966).
    CAS PubMed Google Scholar
  33. Sen, G.C. Viruses and interferons. Annu. Rev. Microbiol. 55, 255–281 (2001).
    CAS PubMed Google Scholar
  34. Reid, E. & Charleston, B. Type I and III interferon production in response to RNA viruses. J. Interferon Cytokine Res. 34, 649–658 (2014).
    CAS PubMed Google Scholar
  35. Nowarski, R. & Kotler, M. APOBEC3 cytidine deaminases in double-strand DNA break repair and cancer promotion. Cancer Res. 73, 3494–3498 (2013).
    CAS PubMed PubMed Central Google Scholar
  36. Dziegielewski, J., Melendy, T. & Beerman, T.A. Bleomycin-induced alterations in DNA replication: relationship to DNA damage. Biochemistry 40, 704–711 (2001).
    CAS PubMed Google Scholar
  37. Mullane, S.A. et al. Correlation of APOBEC mRNA expression with overall survival and PD-L1 expression in urothelial carcinoma. Sci. Rep. 6, 27702 (2016).
    CAS PubMed PubMed Central Google Scholar
  38. Machiela, M.J., Ho, B.M., Fisher, V.A., Hua, X. & Chanock, S.J. Limited evidence that cancer susceptibility regions are preferential targets for somatic mutation. Genome Biol. 16, 193 (2015).
    PubMed PubMed Central Google Scholar
  39. Rahman, N. Realizing the promise of cancer predisposition genes. Nature 505, 302–308 (2014).
    CAS PubMed PubMed Central Google Scholar
  40. Burger, M. et al. Epidemiology and risk factors of urothelial bladder cancer. Eur. Urol. 63, 234–241 (2013).
    PubMed Google Scholar
  41. Garcia-Closas, M. et al. Common genetic polymorphisms modify the effect of smoking on absolute risk of bladder cancer. Cancer Res. 73, 2211–2220 (2013).
    CAS PubMed PubMed Central Google Scholar
  42. Cescon, D.W., Haibe-Kains, B. & Mak, T.W. APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation. Proc. Natl. Acad. Sci. USA 112, 2841–2846 (2015).
    CAS PubMed PubMed Central Google Scholar
  43. Vartanian, J.P., Guétard, D., Henry, M. & Wain-Hobson, S. Evidence for editing of human papillomavirus DNA by APOBEC3 in benign and precancerous lesions. Science 320, 230–233 (2008).
    CAS PubMed Google Scholar
  44. Suspène, R. et al. Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. Proc. Natl. Acad. Sci. USA 102, 8321–8326 (2005).
    PubMed PubMed Central Google Scholar
  45. Waters, C.E., Saldivar, J.C., Amin, Z.A., Schrock, M.S. & Huebner, K. FHIT loss-induced DNA damage creates optimal APOBEC substrates: insights into APOBEC-mediated mutagenesis. Oncotarget 6, 3409–3419 (2015).
    PubMed Google Scholar
  46. Plimack, E.R. et al. Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. Eur. Urol. 68, 959–967 (2015).
    CAS PubMed PubMed Central Google Scholar
  47. Kim, R., Emi, M. & Tanabe, K. Cancer immunoediting from immune surveillance to immune escape. Immunology 121, 1–14 (2007).
    CAS PubMed PubMed Central Google Scholar
  48. Rizvi, N.A. et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer. Science 348, 124–128 (2015).
    CAS PubMed PubMed Central Google Scholar
  49. Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401–404 (2012).
    PubMed Google Scholar
  50. Marx, V. Drilling into big cancer-genome data. Nat. Methods 10, 293–297 (2013).
    CAS PubMed Google Scholar
  51. Bullard, J.H., Purdom, E., Hansen, K.D. & Dudoit, S. Evaluation of statistical methods for normalization and differential expression in mRNA-seq experiments. BMC Bioinformatics 11, 94 (2010).
    PubMed PubMed Central Google Scholar
  52. Shabalin, A.A. Matrix eQTL: ultra fast eQTL analysis via large matrix operations. Bioinformatics 28, 1353–1358 (2012).
    CAS PubMed PubMed Central Google Scholar
  53. Li, Q. et al. Integrative eQTL-based analyses reveal the biology of breast cancer risk loci. Cell 152, 633–641 (2013).
    CAS PubMed PubMed Central Google Scholar
  54. Reva, B., Antipin, Y. & Sander, C. Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res. 39, e118 (2011).
    CAS PubMed PubMed Central Google Scholar

Download references

Acknowledgements

We thank the Breast Cancer Association Consortium (BCAC) for access to summary results for the association between rs1014971 and breast cancer risk. The results presented here are in part based upon data generated by the TCGA Research Network. The study was supported by federal funds from the Intramural Research Program (IRP), Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health (contract HHSN261200800001E). The Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial was funded with National Institutes of Health Genes, Environment, and Health Initiative (GEI) grants HG-06-033-NCI-01 and RO1HL091172-01, U01HG004438, and NIH HHSN268200782096C. The Spanish Bladder Cancer Study (SBCS) was funded with intramural contract NCI N02-CP-11015. FIS/Spain 98/1274, FIS/Spain 00/0745, PI061614, and G03/174, Fundació Marató TV3, Red Temática Investigación Cooperativa en Cáncer (RTICC), Consolíder ONCOBIO, EU-FP7-201663; and RO1-CA089715 and CA34627. The Biobank Japan Project was supported by the Ministry of Education, Culture, Sports, Science and Technology of the Japanese government. The funders did not have a role in study design, data collection and analysis, writing, or submission of the manuscript.

Author information

Author notes

  1. Candace D Middlebrooks and A Rouf Banday: These authors contributed equally to this work.

Authors and Affiliations

  1. Division of Cancer Epidemiology and Genetics, Laboratory of Translational Genomics, National Cancer Institute, US National Institutes of Health, Bethesda, Maryland, USA
    Candace D Middlebrooks, A Rouf Banday, Krizia-Ivana Udquim, Olusegun O Onabajo, Ashley Paquin & Ludmila Prokunina-Olsson
  2. Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan
    Konichi Matsuda
  3. Usher Institute of Population Health Sciences and Informatics, Medical School, University of Edinburgh, Edinburgh, UK
    Jonine D Figueroa
  4. Division of Cancer Epidemiology and Genetics, National Cancer Institute, US National Institutes of Health, Bethesda, Maryland, USA
    Bin Zhu, Stella Koutros, Neal D Freedman, Stephen J Chanock, Montserrat Garcia-Closas, Debra T Silverman & Nathaniel Rothman
  5. Center for Integrative Medical Science, Institute of Physical and Chemical Research (RIKEN), Kanagawa, Japan
    Michiaki Kubo
  6. Department of Urology, School of Medicine, Kochi University, Kochi, Japan
    Taro Shuin
  7. Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain
    Manolis Kogevinas
  8. Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain
    Manolis Kogevinas
  9. Epidemiología y Salud Pública (CIBERESP), Centro de Investigación Biomédica en Red (CIBER), Madrid, Spain
    Manolis Kogevinas
  10. Spanish National Cancer Research Centre (CNIO), Madrid, Spain
    Nuria Malats

Authors

  1. Candace D Middlebrooks
    You can also search for this author inPubMed Google Scholar
  2. A Rouf Banday
    You can also search for this author inPubMed Google Scholar
  3. Konichi Matsuda
    You can also search for this author inPubMed Google Scholar
  4. Krizia-Ivana Udquim
    You can also search for this author inPubMed Google Scholar
  5. Olusegun O Onabajo
    You can also search for this author inPubMed Google Scholar
  6. Ashley Paquin
    You can also search for this author inPubMed Google Scholar
  7. Jonine D Figueroa
    You can also search for this author inPubMed Google Scholar
  8. Bin Zhu
    You can also search for this author inPubMed Google Scholar
  9. Stella Koutros
    You can also search for this author inPubMed Google Scholar
  10. Michiaki Kubo
    You can also search for this author inPubMed Google Scholar
  11. Taro Shuin
    You can also search for this author inPubMed Google Scholar
  12. Neal D Freedman
    You can also search for this author inPubMed Google Scholar
  13. Manolis Kogevinas
    You can also search for this author inPubMed Google Scholar
  14. Nuria Malats
    You can also search for this author inPubMed Google Scholar
  15. Stephen J Chanock
    You can also search for this author inPubMed Google Scholar
  16. Montserrat Garcia-Closas
    You can also search for this author inPubMed Google Scholar
  17. Debra T Silverman
    You can also search for this author inPubMed Google Scholar
  18. Nathaniel Rothman
    You can also search for this author inPubMed Google Scholar
  19. Ludmila Prokunina-Olsson
    You can also search for this author inPubMed Google Scholar

Contributions

L.P.-O., A.R.B., and C.D.M. designed the study and performed genetic and molecular analysis of public and laboratory-generated data. A.R.B., K.M., K.-I.U., and A.P. performed genotyping of germline variants. A.R.B., K.-I.U., and O.O.O. performed functional experiments. B.Z. contributed analytical tools. J.D.F., S.K., M. Kubo, T.S., N.D.F., M. Kogevinas, N.M., S.J.C., M.G.-C., D.T.S., and N.R. contributed samples and data. L.P.-O., A.R.B., and C.D.M. wrote the manuscript. All authors have read and approved the final version of the manuscript.

Corresponding author

Correspondence toLudmila Prokunina-Olsson.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Integrated supplementary information

Supplementary Figure 1 LD (_r_2) between the A3AB deletion and all markers in a 400-kb APOBEC3 region in 1000 Genomes Project populations.

Populations: CEU, individuals of European ancestry from Utah, only samples that overlapped with the HapMap set are used here; CHB, Chinese from Beijing; JPT, Japanese from Tokyo. All samples were genotyped with a CNV assay; genotypes for all other markers were generated by the 1000 Genomes Project (October 2014 release). SNP rs12628403 is the only marker that tags the deletion in Europeans and Japanese (_r_2 = 1.0) and Chinese (_r_2 = 0.95). In the Yoruba (YRI) panel of the 1000 Genomes Project, the CNV is weakly polymorphic (4.2%) while rs12628403 is monomorphic, and LD metrics could not be calculated. SNP rs12628403 was also genotyped by a custom TaqMan assay (Supplementary Note), and all genotypes were 100% concordant with data from the 1000 Genomes Project.

Supplementary Figure 2 LD (_r_2) between the A3AB deletion, its proxy SNP rs12628403, and all GWAS-genotyped and imputed markers within a 400-kb APOBEC3 genomic region on chromosome 22q13.1.

The plot is based on 848 genotyped or imputed markers in 1,837 samples from individuals of European ancestry from the PLCO study in which the deletion (gray box) was genotyped by a CNV assay and its proxy SNP, rs12628403, was genotyped by a TaqMan genotyping assay. In this set, the CNV and rs12628403 have _r_2 = 0.92 and _D_′ = 0.97. Because of low LD with other markers in this region (best _r_2 ~0.2), the deletion and its proxy SNP, rs12628403, cannot be imputed and have to be genotyped.

Supplementary Figure 3 Electrophoretic mobility shift assays for SNP rs1014971 with nuclear extracts from bladder cancer cell line HTB-9 and breast cancer cell lines MDA-MB-231 and T-47D.

Supplementary Figure 4 Expression of selected APOBEC3 genes (A3A, A3B, and A3G) in GTEx.

Expression analysis in 8,555 samples (53 normal human tissues from 544 donors) based on data generated by the Genotype-Tissue Expression (GTEx) Project. Expression is measured by RNA–seq and presented as normalized log10 (FPKM) values. Expression in bladder and breast tissue samples is marked by red boxes. Data for colon–transverse tissue were available only for A3A and are labeled separately, while data for expression of A3A were not available for adipose–visceral tissue.

Supplementary Figure 5 Expression of selected APOBEC3 genes (A3A, A3B, and A3G) in bladder cancer cell lines RT-4 and HTB-9 infected with Sendai virus (SeV) or treated with the DNA-damaging drug bleomycin (Bleo).

(a,c) Increase in expression of a viral-specific RNA shows that cells were successfully infected with SeV. (b,d) In untreated cells, baseline expression of A3A is significantly lower than that of A3B and A3G. (e,g) A3A and A3G but not A3B are significantly induced after 12 h of SeV infection. (f,h) Expression of A3A, A3B, and A3G is significantly induced by 24 h of treatment with bleomycin as compared to untreated (UT) samples. Plots present expression values (Δ_C_t, log2 scale) for targets (A3A, A3B, and A3G) normalized by the geometric mean of expression for two endogenous controls (GAPDH and PPIA). Dotted lines indicate the lower level of detection for the targets—a _C_t value of 40 was assigned to samples for which expression was not detected by 40 cycles of qRT–PCR; individual plot points for these samples are defined by the levels of expression of endogenous controls. All experiments were performed in biological triplicate. P values are for two-sided t tests. Shown are values for individual replicates and means. Raw data are available in Supplementary Data 2.

Supplementary Figure 6 Expression of selected APOBEC3 genes (A3A, A3B, and A3G) in breast cancer cell lines MDA-MB-231 and T-47D infected with Sendai virus or treated with the DNA-damaging drug bleomycin.

(a,c) Increase in expression of a viral-specific RNA shows that cells were successfully infected with SeV. (b,d) In untreated cells, A3B expression is significantly higher than that of A3A and A3G. (e,g) Only A3A in MDA-MB-231 cells and all APOBEC genes in T-47D cells are significantly induced after 12 h of SeV infection. (f,h) Only A3B and A3G in MDA-MB-231 cells and all APOBEC genes in T-47D cells are significantly induced by 24 h of treatment with bleomycin as compared to untreated (UT) samples. Plots present expression values (Δ_C_t, log2 scale) for targets (A3A, A3B, and A3G) normalized by the geometric mean of expression for two endogenous controls (GAPDH and PPIA). Dotted lines indicate the lower level of detection for the targets—a _C_t value of 40 was assigned to samples for which expression was not detected by 40 cycles of qRT–PCR; individual plot points for these samples are defined by the level of expression of endogenous controls. All experiments were performed in biological quadruplicate. P values are for two-sided t tests. Shown are values for individual replicates and means. NE, not expressed in all samples. Raw data are available in Supplementary Data 2.

Supplementary Figure 7 APOBEC mutagenesis and SNP rs17000526 as predictors of overall survival for patients with breast cancer in TCGA.

(ah) Results are presented separately for patients with ER+ (ad) and ER− (eh) tumors. (a,e) Overall survival in relation to quartiles of APOBEC-signature mutation counts. (b,f) Overall survival in relation to APOBEC mutagenesis pattern classified as “no” or “yes” (at least one mutation present). (c,g) Overall survival in relation to APOBEC mutagenesis pattern classified as “no,” “low mutation counts” (1–48 mutations) or “high mutation counts” (≥49 mutations; based on the median in bladder tumors, presented in Fig. 5b). (d,h) Overall survival in relation to rs17000526. Hazards ratios and P values are for multivariate Cox regression models that also include age and tumor stage as core variables.

Supplementary information

Supplementary Text and Figures

Supplementary Figures 1–7, Supplementary Tables 3–20 and Supplementary Note. (PDF 3510 kb)

Supplementary Table 1

Association with bladder cancer risk for top genotyped or imputed markers within 1 Mb of the 22q13.1 region. (XLSX 22 kb)

Supplementary Table 2

Genotypes of A3AB deletion (CNV) and SNP rs12628403 in HapMap populations. (XLSX 53 kb)

Supplementary Data 1

Data source for analyses in TCGA bladder tumors. Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors. (XLSX 1214 kb)

Supplementary Data 2

Source file for analyses. Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors. (XLSX 301 kb)

Rights and permissions

About this article

Cite this article

Middlebrooks, C., Banday, A., Matsuda, K. et al. Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors.Nat Genet 48, 1330–1338 (2016). https://doi.org/10.1038/ng.3670

Download citation